Alabama House Bill HB127

Alabama 2026 Regular Session

• Introduced: 1/7/26
• Introduced: 1/13/26
• Refer: 1/7/26
• Refer: 1/13/26

Caption

Pharmaceuticals; prohibiting the Board of Pharmacy from disciplining pharmacists who recommend off-label use of a drug; allowing over-the-counter sale of Ivermectin and Hydroxychloroquine.

Impact

Should HB 127 be enacted, it would have significant implications for state pharmacy laws and professional practice in the pharmaceutical field. By limiting the power of the Board of Pharmacy, the bill may encourage more pharmacists to offer off-label drug recommendations. This could potentially expand treatment options available to patients but may also raise concerns regarding patient safety and the professional responsibilities of pharmacists. Critics argue that this could lead to inappropriate drug usage among patients if pharmacists are encouraged to recommend off-label uses without adequate guidance or regulatory oversight.

Summary

House Bill 127 addresses the regulatory authority of the state’s Board of Pharmacy as it pertains to the discipline of pharmacists. Specifically, the bill prohibits the Board from taking disciplinary actions against pharmacists who recommend the off-label use of drugs. This legislation arises from ongoing debates regarding the appropriateness and legality of off-label prescriptions, especially concerning the medications Ivermectin and Hydroxychloroquine. The proponents of the bill argue that pharmacists should have the autonomy to provide recommendations that could benefit patients without fear of retribution from regulatory bodies.

Contention

The discussion surrounding HB 127 highlights a critical tension between regulatory oversight and professional autonomy in the pharmacy sector. Advocates for the bill contend that pharmacists, as healthcare professionals, should be trusted to use their clinical judgment in recommending treatments for their patients, especially in cases where traditional protocols may not provide effective solutions. In contrast, opponents express worries that this bill undermines public health standards by circumventing necessary checks on drug use and could lead to potential misuse of medications that lack sufficient evidence for certain therapeutic applications.